FDA Approves Levoleucovorin for Injection for mCRC, Osteosarcoma

On October 23, the FDA approved levoleucovorin for injection (Khapzory, Spectrum Pharmaceuticals, Inc.) for three indications:

  • Rescue after high-dose methotrexate therapy in patients with osteosarcoma
  • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination
  • The treatment of patients with metastatic colorectal cancer (mCRC) in combination with fluorouracil.

Read the Spectrum Pharmaceuticals press release here.

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington